99 filings
Page 2 of 5
PRE 14A
uyfnc7
10 Apr 23
Preliminary proxy
4:31pm
8-K
rqn6y
10 Apr 23
Departure of Directors or Certain Officers
4:30pm
8-K
9mg7jega
18 Jan 23
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
4:36pm
8-K
dsvkpglr
6 Dec 22
Designation Represents Potential to Bring Important New Therapy to Patients Earlier
4:23pm
8-K
3rk4bjymqrrboyd70qbl
30 Nov 22
Cost Associated with Exit or Disposal Activities
4:32pm
8-K
yn3jngax jsend3b4gf6
6 Sep 22
SQZ Biotechnologies Announces Leadership Transition
4:33pm
8-K
tbch8nu9 3ssip7
11 Jul 22
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
4:49pm
8-K
ozn1ejmy22jq3p 2n41
16 Jun 22
Submission of Matters to a Vote of Security Holders
8:19am
8-K
tne6q yq4kbrdjdy2nri
31 May 22
Experienced Drug Developer Brings Over 25 Years of Clinical Development Industry Knowledge Across Oncology, Immunology, and Infectious Disease
4:52pm
8-K
x9ipr7jnfk5i
19 May 22
Regulation FD Disclosure
4:05pm
DEFA14A
6ntxtsgg
26 Apr 22
Additional proxy soliciting materials
5:08pm
8-K
dhjbqxh
24 Jan 22
SQZ Biotechnologies Announces FDA Clearance of Investigational New Drug (IND) Application for SQZ-eAPC-HPV, a Novel mRNA-based Cell Therapy for the Treatment of HPV16 Positive Solid Tumors
7:01am
8-K
ebcxz3bt5xch2lehj86
9 Dec 21
Other Events
7:30am
8-K
p0ibx doe
2 Dec 21
Other Events
6:28am